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Prediction of steady-state verapamil plasma concentrations 
in children and adults 
With data on adults from two previous articles it was found that the average steady-state plasma 
concentration of verapamil in subjects on long-term oral therapy of 80 mg every 6 hr (Y) 
correlated strongly with the area under the curve from zero to infinity (AUC'16 (X) where the 
area refers to that for a single oral dose of 80 mg (i> = 2.41X, n =- 15, r = 0.923, 
P <0.001). Steady-state concentrations are predictable from the single-dose data, with an 
average absolute deviation of 11.1%. We gave seven children (7 to 19 yr old) an initial 
intravenous bolus dose of 0.1 mg /kg, followed by a 20-min constant rate infusion of 0.007 
mglkglmin. Twenty-four hours after the bolus dose they were put on oral therapy (40 or 80 mg 
every 6 hr) and 1 mo later the minimum steady-state verapamil plasma concentration (C") was 
measured. Plasma concentration-time data obtained after the infusion were fitted to 
biexponential (two sets) or triexponential equations (five sets). The coefficients of the 
postinfusion polyexponential equations were converted to those for the 0.1-mg/kg bolus dose 
alone. Mean parameters estimated were: plasma clearance 0.500 Ilmin, steady-state volume of 
distribution 279 1, Vo 394 I, half-life 9.17 hr, and mean residence time 10.0 hr. Many 
correlations were made between the oral CV" values and functions obtained from the 
intravenous data. The best correlation was that between C!" and the predicted steady-state 
concentration at 3 hr after dosing when bolus doses would be given at 6-hr intervals based on 
the single-dose intravenous data (r = 0.985, P < 0.001); this correlation allowed C' to be 
predicted with an average absolute deviation of 10%. Norverapamil was measured in plasma 
after oral dosing, but was not detectable after intravenous dosing. 
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specifically, sarcolemmal calcium stores in the 
myocardium and is remarkably effective in pre- 
venting coronary spasm' and in treating patients 
with hypertrophic cardiomyopathies. 
Verapamil kinetics have been studied in dogs 
and the changes in arterioventricular conduction 
time, as estimated from the PR interval of the 
surface ECG, have been correlated with the log- 
arithm of the plasma verapamil concentration. '° 
The kinetics of the drug were also studied in nor- 




AUC"-': Total area under the 
concentration-time curve 
AUC': AUC in dose interval at steady- 
state 
Cl:a Steady-state oral clearance 
Cla: Single-dose oral clearance 
C: Steady-state concentration 
CmlsTh Minimum steady-state 
concentration 
C: Predicted plasma concentration 
after intravenous dosing 
Vss: Volume of distribution at steady 
state 
GLC: Gas-liquid chromatography 
r2: Coefficient of determination 
D0/D: Oral/intravenous dose ratio 
t1/2: Half-life 
mal subjects and patients,1-3, 5-7, 11, 12, 14, 15, 22,23 
but kinetics in children have not been reported 
to date. 
Koup et al. ,8' 9 Slattery et al. ,17 and Slattery18 
have been remarkably successful in predicting 
the maintenance dose required to attain a desired 
drug from a single determination of concen- 
tration after an initial dose. They have also suc- 
cessfully predicted clearance of chlorampheni- 
col in infants and children from a single serum 
sample obtained 6 hr after the initial intravenous 
dose. Indirectly such correlations involve relat- 
ing Cm of a drug to a single concentration mea- 
sured after an initial dose. 
Recently both Freedman et al.5 and Shand 
et al.15 reported that there is a marked reduction 
in verapamil clearance between the time of the 
first dose and attainment of steady state. As a re- 
sult of this, Freedman et al. stated that "kinetic 
predictions based on single doses will not give 
reliable estimates for long-term oral dosage. "5 
We examined this hypothesis in adults, using the 
published data of Freedman et al. and Shand 
et al., and in children, using single-dose intrave- 
nous and steady-state oral data we obtained. 
Methods 
Adults. Freedman et al. reported the plasma 
verapamil AUC° after a single oral dose (D,) 
of 80 mg in nine subjects and the AUC°' after 
long-term oral doses of 80 mg every 6 hr to the 
same nine subjects. Shand et al. reported 
Prediction of verapamil steady-state levels 173 
AUC° after an initial oral dose of 120 mg 
verapamil in six patients and AUC°' after the 
seventh dose of 120 mg every 8 hr in the same 
patients. We estimated both Cls and C11,so from 
D,/(AUC°) and D,/(AUCo-r) from each of 
the 15 pooled data sets, then correlated C11,s0 with 
C4,0 using the standard least-squares linear re- 
gression method. In addition, the data of Shand 
et al. were dose adjusted to what would be ex- 
pected for a unit dose of 80 mg, rather than 120 
mg, by multiplying the AUCs by 80/120. The 
average Css was then estimated as AUC°-6/6 
with the AUC°" values of Freedman et al., and 
in a similar manner from the data of Shand et al., 
but using the adjusted areas rather than AUC" 
and 6 rather than 8 hr. These Cs, values were 
correlated with AUC° /6 values by standard 
least-squares linear regression and least-squares 
regression where the line is forced through the 
0,0 point; for the Shand et al. data the dose- 
adjusted AUC°-'s were used in this correlation. 
Children. Our subjects were seven children 
(two girls; five boys; 7 to 19 yr old; mean age 12 
yr) with documented hypertrophic cardiomy- 
opathy. Five of the seven patients were found at 
the time of cardiac catheterization to have a rest- 
ing systolic left ventricular outflow tract gra- 
dient greater than 10 mm Hg. All patients were 
symptomatic as a result of their disease. The 
symptoms included: marked resting or postex- 
ertional dyspnea (all seven patients), chest pain 
(six patients), and one or more syncopal epi- 
sodes (four patients). 
Routine biochemical investigations revealed 
normal renal and hepatic function in all pa- 
tients. No medications were taken in the preced- 
ing 48 hr. All studies were performed in the 
fasting state and all seven patients were given 
morphine sulfate and diphenhydramine as pre- 
medication. 
Verapamil was given intravenously to all pa- 
tients at the time of cardiac catheterization. 
Verapamil HC1 was injected as an initial intra- 
venous bolus of 0.1 mg/kg over 2 min, fol- 
lowed by a 20-min continuous infusion of 0.007 
mg/kg/min The ECG, systemic arterial, left 
ventricular, and pulmonary artery pressures 
were continuously monitored. Blood samples (5 
to 7 ml) were drawn before verapamil, just as 
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Fig. 1. Plot for prediction of average plasma of 
verapamil from single-dose oral data in adults. Dia- 
monds represent data of Freedman et al.5 and circles 
of Shand et al.'5 Equation of line is Y = 2.41X 
(n = 15, r = 0.923, P < 0.001). 
0.5, I, 2, 4, 8, 12, 16, 18, and 22 hr after the 
infusion. Blood was transferred to heparinized 
tubes and centrifuged and the plasma was stored 
at 20° until analyzed. Oral dosage was initi- 
ated (either 40 or 80 mg every 6 hr) 24 hr after 
the bolus dose and a month later a blood sample 
was taken at 6 hr after a dose at steady state. 
The latter samples provided the CVn. In one 
patient (Bo) a single oral dose of 40 mg of ver- 
apamil was given 24 hr after the intravenous 
bolus dose and initiation of the 20-min infusion. 
For this patient blood was also collected just 
before oral dosing (0 time) and at 0.25, 0.5, 
0.75, 1, 2, 3, and 4 hr after dosing. Verapamil 
and norverapamil were measured in plasma by a 
sensitive and specific GLC procedure with a 
nitrogen-sensitive detector.' 9 
Postinfusion verapamil plasma concentra- 
tions were computer fitted by the method of 
least-squares as follows: 
= 7 e--kt (1) 
i = I 
where n = 2 or 3, Zi is the coefficient of the ith 
term, Ai is the exponent of the ith term, and t is 
time measured from the end of the infusion. 
Some data sets were fitted with the program 











Fig. 2. Semilogarithmic plots of postinfusion data of 
patients Me (circles) and T (diamonds). Lines are 
computer-fitted concentrations based on equation 1 
and the Z, and Ai values shown in Table II. 
digital computer; the others were fitted with a 
program written by Dr. J. L. Fox using an 
Apple II Plus microcomputer. The Zi co- 
efficients were converted to Ci coefficients by 
the method of Singhvi'6 to provide: 
C!,v = C, e-x,, (2) 
where the Cis correspond to a bolus dose of 0.1 
mg/kg of verapamil only and t is now time after 
the bolus dose (see footnote to Table II). 
A large number of correlations were made to 
find the optimum parameter to predict the ver- 
apamil plasma CVns after long-term oral ther- 
apy from the intravenous data. In each case the 
observed CIL'ins were used as the X (abscissa) 
values and an estimated intravenous concentra- 
tion, corresponding to the oral dose, was calcu- 
lated from the fitted parameters (coefficients 
and exponents) obtained from the single-dose 
intravenous data and used as the Y (ordinate) 
values. (The estimated intravenous concentra- 
tions used are explained in columns 2 and 3 of, 
and in the footnotes to, Table VI.) 
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Table I. Verapamil plasma concentrations measured after infusion of a bolus dose 
of 0.1 mg/kg and an infusion of 0.007 mglkglmin over 20 min 
Results 
Adults. The correlation of Y = C1r0 with 
X = C4,0 gave the regression line S' = 
0.421X - 0.044 (r = 0.932, P < 0.001); the 
intercept did not differ significantly from zero. 
The least-squares line forced through the 0,0 
point gave the regression line Y = 0.411X 
(n = 15; r = 0.932; P < 0.001). This correla- 
tion (graph not shown) and the random scatter 
of the six points from the Shand et al. data about 
the regression line (three of the six points were 
essentially on the regression line) indicated that 
adjustments to dosage and dosage interval data 
to make them compatible with those of Freed- 
man et al. were justifiable. 
Correlation of Y = C with X = AUC°-'/6 
by the method of least squares forced through 
the 0,0 point gave the regression line Y = 
2.41X (n = 15; r -= 0.923; P < 0.001). The 
plot is shown as Fig. 1. The mean absolute (sign 
ignored) deviation of a predicted from the 
observed C concentration was 18.4 ng/ml or 
11.1%. It should be noted that the reciprocal of 
the slope of the Ciro vs C10 regression, namely 
1/0.411 = 2.43, is essentially identical with 
the slope 2.41 of the vs AUC°-'/6 regres- 
sion, as expected. 
Children. Table I lists the verapamil plasma 
concentrations measured after infusion follow- 
*Points used to estimate the parameters of the equation C = C e-AzI in Table V. Parameters were estimated by least squares 
regression with the equation In C -= In - X, t. 
ing the bolus dose of 0.1 mg/kg and constant- 
rate infusion of 0.14 mg/kg (total intravenous 
dose, 0.24 mg/kg) given over 20 min. Table II 
gives the results of computer fitting of the data 
shown in Table Ito equation 1 and also the Ci 
values corresponding to equation 2 and a single 
0.1-mg/kg bolus intravenous dose of verapa- 
mil. The sum of squared deviations and r2s for 
the fits are also listed in Table II. The last row in 
Table II lists the percentage contribution of the 
terminal log-linear phase, i.e., the Cie-x" term, 
to the AUC°- corresponding to a single 
0.1-ng/kg bolus dose. Results of fitting two of 
the seven sets of postinfusion data are shown in 
Fig. 2. 
By the use of the intravenous dose of 0.1 
mg/kg and the Ci and Xi values of Table II, 
kinetic parameters for verapamil in children 
were estimated by established methods20. 21 and 
are listed in Table III. In addition, the last row 
of Table III lists the percentage of error in the 
clearance of verapamil if only the monoexpo- 
nential equation Cp = C1et is used rather 
than the polyexponential equation 2 (see foot- 
note to Table III for the appropriate equations to 
make such estimates). 
Table IV lists the oral doses given to the 
children, the Dpp/Divs used in subsequent corre- 




Plasma concentration (nglml) 
Subject 
Ma Bu V Me Bo 
0 253 304 120 268 101 258 56 
0.1 140 131 45 
0.25 89 116 60 114 32 82 -- 
0.5 51 72 24 99 25 57 -- 
1 36 -- 52 10.4 51 26* 
2 26 64 19* 47 4.45* 36* 20* 
4 13.4* 56* 16* 24* 3.6* 12* 
8 11.25* -- 14* 13.5* 1.6* 18* 10 
12 7.6* 15* 9.5* 5.1* 13.4* -- 
16 8.0* 
18 6.2* 2.6* 0.4* 
22 6.0 
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Table II. Parameters from nonlinear least-squares fitting of postinfusion verapamil plasma 
concentrations after a bolus dose of 0.1 mg/kg and the infusion of 0.14 mg/kg given 
at a rate of 0.42 mg/kg/hr (0.007 mglkglmin) over 0.333 hr (20 min) 
) = 1 
apamil and norverapamil after 1 mo of oral 
therapy. 
With the starred terminal postinfusion plasma 
concentrations shown in Table I and the equa- 
tion shown in the footnote to Table I, the pa- 
rameters Co, Xz, and the t1/2 (0.693/Xz) were 
estimated and are shown in Table V. In six of 
Clin. Pharmacol. Titer. 
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Values in parenthesis are SDs of estimated parameters. The equation fitted to postinfusion plasma concentrations of verapamil was: 
C = Z, e-At, where n = 2 or 3 and t = time after cessation of the infusion. The corresponding equation if only the 0.1-mg/kg bolus dose had 
V= 1 
z, 
been administered is: C = C, e",t, where t = time after injection and C, - . CV = coefficient of variation; 4.2 (4.2 
- - 1) e-°.332)' 
Idev2 = sum of squared deviations. 
*Data were fitted with the Apple 11 microcomputer using a program written by Dr. J. L. Fox using equal weights. 
tData were fitted with the program NONLIN written by Dr. C. M. Metzler using the central campus computer with weighting according to 
the reciprocals of the concentrations. 
No SDs were obtained since there were too few data points for the number of estimated parameters. 
§No SDs were obtained as a result of a problem with the computer program. 
11 - 1 - Idse2v2, where s = IC? - (/C1)2/N. 
11% Contribution = 100 -c, /AUC'-', where AUC'-' = /X, corresponding to the 0.1-mg/kg IV bolus dose. 
our seven children the t1/2 estimated as 0.693/X 
was shorter than that estimated as 0.693/X1 
(Table III). The mean t1/2 (0.693/X5) of 6.40 hr 
and mean t1/2 (0.693/X1) of 9.17 hr differed by 
paired t test (P = 0.05). This suggests that 
polyexponential fitting is necessary to estimate 
the appropriate elimination rate constant and t1/2. 
Parameter 
Subject 
Ma* But V* 
X1 (hr') 0.0391 0.0737 0.0405 
(0.0316) (0.0518) 
X2(hr--1) 0.569 3.36 4.07 
(0.168) 
X3(hr) 6.37 8.62 
(0.332) 
Z1 (ng/ml) 12.78 74.97 17.90 
(5.14) (5.87) 
Z2 (ng/ml) 40.96 100.6 103.0 
(4.92) (7.78) 
Z3 (ng/ml) 199.3 139.4 
(5.51) 
C1 (ng/ml) 5.325 31.80 7.534 
C2 (ng/ml) 19.49 86.11 100.6 
C3 (ng/ml) 284.7 587.4 
/dev2 6.96 39.2 85.3 
0.9999 0.9991 0.9956 
AUC' (1X hr) 215 525 211 
for 0.1-mg/kg IV 
bolus dose 
% Contribution of terminal 63.3 82.2 88.2 
log-linear phase to the 
AUC°-11 for 0.1-mg/kg IV 
bolus dose 
Table VI summarizes results of the best cor- 
relations of the oral CEIn values with functions 
derived from the single-dose intravenous data in 
children. The best correlation is that of row A of 
Table VI and the correlations become progres- 
sively poorer as one proceeds to row F. Corre- 
lations were made with the functions shown in 
the third column of Table VI at various times t 
and only the best correlation (optimum t value) 
of each type is shown in the table. The functions 
are as follows: (A) plasma verapamil CV at 3 hr 
after dosing when bolus intravenous doses are 
given every 6 hr, (B) plasma verapamil CV at 3 
hr after dosing when both bolus doses and infu- 
sions are given intravenously, as in our pro- 
tocol, (C) plasma verapamil CV at 12 hr after a 
single intravenous bolus dose, (D) plasma ver- 
apamil CV at 12 hr after a bolus dose and an 
infusion, as in our protocol, (E) as in function A 
except only terminal intravenous data are used 
(Table V) and t = 4 hr rather than 3 hr, and (F) 
as in function C except only terminal intrave- 
nous data are used and t = 9 hr rather than 12 
hr. In all the correlations the predicted intrave- 
nous concentrations correspond to the oral 
doses (as a result of the use of the D,,/Div ratios 
shown in Table IV). Confirmation of these cor- 
relations should not be attempted by experimen- 
tal means since the oral doses are too high to be 
given intravenously, but a lower dose could be 
given and the dose ratio Dpo/Div could be used 
to correct the measured values. It should be 
noted that as the r2 and r values decrease, the 
mean absolute deviations in a predicted CVn 
increase considerably (Table VI). 
Table VII lists the verapamil and nor- 
verapamil plasma concentrations in patient Bo, 
who was given an oral dose of 40 mg of ver- 
apamil 24 hr after the intravenous doses. The 
equation fitting the verapamil data (footnote to 
Subject 
Mean CV (%) Met Tt H* Bot 
0.197 0.160 0.0865 0.167 0.109 59.3 
(0.238) (0.0281) (0.0493) 
1.80 2.605 0.949 4.70 2.58 60.5 
(24.8) (0.563) (2.19) 
114.3 4.56 11.15 
(56.9) (0.941) 
57.35 (6.265 36.08 28.70 
(9.81) (11.5) (3.97) 
95.88 51.05 40.99 27.18 
(1.8 x 103) (9.74) (4.73) 
114.7 44.31 180.7 
(1.8 x 103) (9.16) 
25.04 2.712 15.35 12.44 
59.88 37.67 21.26 29.68 
3121. 49.03 461.1 
228.3 70.3 32.5 15.9 
0.9961 0.9991 0.9994 0.9908 
188 42.2 241 180 229 63.6 
67.7 40.2 73.6 41.4 65.2 28.6 
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Table III. Verapamil kinetics estimated from doses, body weights, and the data in Table II 
Table VII) has 0.337 hr-1 as the smallest A, 
value, which corresponds to a t1/2 of 2 hr. Since 
this t1/2 is considerably smaller than any other 
measured (Tables III and VI), we concluded 
that the 4-hr sampling period was insufficient to 
define the log-linear phase. 
Discussion 
Adults. The hypothesis of Freedman et al. 
that "kinetic predictions based on single doses 
will not give reliable estimates for long-term 
oral dosage "5 appears untenable in light of 
Fig. 1. From usual linear kinetic theory one 
would expect the slope of the line in Fig. 1 to be 
equal to unity. However, the fact that the slope 
is 2.41 does not detract from the excellent pre- 
dictability of plasma verapamil Cs after long- 
term oral therapy from the concentrations mea- 
sured after a single dose of the drug. The slope 
of 2.41 indicates that the plasma clearance of 
verapamil decreases 2.4-fold (from 3.6 to 1.5 
//min) during the time from administration of 
the single or first dose to the steady state as 
clearly pointed out by Freedman et al. and 
Pharmacol. Titer. 
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V9 = plasma volume; V = volume of distribution at steady state; VO = volume of distribution area; V,, = volume of distribution 
extrapolated. 
*Elimination 11/2 = 0.693/A1. 
t MRT = mean residence time = /(C,A)A(C,/X,) (see Table ll for C, and A, values). 
$% Error = 100 [( - - + ) for triexponential equation: C = + C,e-xtt + C3e--x,,` and % error = 100 [ for biex- C, X2 s 
ponential equation; C = e-^ + C,e-Att. 
Shand et al. The remarkable thing indicated by 
the correlation is the relative uniformity of the 
fractional or percentage reduction in oral clear- 
ance (or increase in AUC per 80 mg oral dose) 
from person to person. The correlation in Fig. 1 
involves only oral dosing, hence the first-pass 
effect is involved in both the single-dose and 
steady-state results. However, some or all of the 
factors involved in the first pass, namely bio- 
availability (or extraction ratio), hepatic clear- 
ance, and possibly effective liver blood flow, 
must change considerably to account for the 
slope of 2.41. Since the individual subject ver- 
apamil plasma concentrations after the single or 
first doses and those obtained at steady state 
were not available in the articles of Freedman 
et al. and Shand et al., single-point correlations, 
as described by others,9' 9' 17' 18 could not be 
studied, but such studies may be fruitful. 
Children. Since there is extensive first-pass 
metabolism of verapamil the challenge to pre- 
dict CZ," for long-term oral therapy from 
single-dose intravenous data was considerable. 





(%) Ma Bu V Me T H Bo 
Total IV dose 23.0 
(mg 
16.7 11.8 16.3 5.40 11.8 8.16 13.3 44.3 
Age (yr) 19 16 12 15 7 8 10 12 37 
Body wt. (kg) 95.8 69.5 49.1 67.9 22.5 49.1 34.0 55.4 44.3 
Clearance 0.742 0.221 0.389 0.604 0.888 0.339 0.315 0.500 49.7 
(//min) 
V, (1) 31.0 9.88 45.4 2.12 25.2 9.88 80.8 29.2 93.0 
Vss (1) 735 148 509 128 144 175 111 279 87.6 
V/3 (1) 1139 180 576 184 333 235 113 394 91.9 
V de xt (I) 1800 219 653 271 830 319 115 601 97.6 
t1/2* (hr) 17.7 9.40 17.1 3.51 4.33 8.01 4.15 9.17 65.7 
MRT1- (hr) 16.5 11.2 21.8 3.53 2.70 8.60 5.87 10.0 70.4 






58.0 21.7 13.3 47.7 149 35.9 8.5 47.7 101 
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Table IV. Oral doses and plasma Cris of verapamil and norverapatnil after approximately 
I mo of oral dosing 
trations at a given time after infusion (Table I) 
were correlated with the CV's after 1 mo of 
oral therapy (Table IV), the best correlation was 
obtained for t = 4 hr and for that correlation 
(r3 = 0.751). The latter is lower than any r3 
value in Table VI. Hence, for accurate predic- 
tion of oral Csss polyexponential fitting of the 
intravenous single-dose data was necessary. 
The concept of "mapping" the parameter space 
(varying time t in the functions of Table VI) to 
uncover the optimum time after dosing to use in 
correlations of Cs with these other parameters 
obtained from single-dose data appears to be 
novel. This approach with the children's ver- 
apamil data has disclosed that, at least in this 
case, projecting single-dose intravenous data to 
steady state (A and B, Table VII) considerably 
improves predictability-i.e., provides higher 
1-2 values. Also, when estimated intravenous 
concentrations at different times after a single 
dose were used in the correlations the predict- 
ability appeared to improve as time after dosing 
increased, but 1-2 appeared to approach an 
asymptotic value as t increased. Such informa- 
tion may be useful in correlations of the type 
described by other authors.8' 9' 17' 18 
Our observations, listed in Table VII, con- 
cerning length of the blood sampling time are 
related to other observations we have made 
concerning data in the literature. The 6-hr sam- 
pling period of Dominic et al.' was not long 
enough to reach the true log-linear phase since 
they reported an average t1/2 of 1.8 hr, which is 
considerably shorter than that reported by 
others.2, 3, 5, 6. 11, 15. 22 The mean elimination t1/2 
of 9.17 hr that we obtained in children by 
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Table V. Parameters of the equation 
C = Coe-A,t estimated from terminal 
postinfusion data only* 
*See footnote to Table 1 for data used. 
polyexponential fitting was longer than the 
mean t1/2 of 6.40 hr that we obtained by use of 
only terminal concentrations; even the latter is 
longer than the t1/2 in adults reported by 
others.1-3, 5, 6, 11, 15, 22 The mean clearance of 
0.500 //min we found in the seven children is 
also lower than the mean clearances in the range 
0.576 to 1.57 //min reported for adults by 
others.1, 3, 5, 6, 11, 22 Thus, it appears that both 
the clearance and elimination rate constant of 
verapamil may be smaller in children than in 
adults. This is so even when it is normalized to 
body weight; the mean clearance was 11.9 
(7.32 omitting patient T) ml/min/kg in the 
seven (or six) children. In general, evaluation of 
our child data and the adult data of Eichbaum 
et al.3 and Kates et al.6 indicated that normaliz- 
ing clearances and volumes of distribution of 
verapamil for body weight does not lower coef- 
ficients of variation, but, in fact, usually raises 
D, q.i.d. "Is us 
Subject mg mg/kg D ir* Verapamil Norverapamil 
Ma 80 0.835 3.48 99 129 
Bu 80 1.15 4.79 225 159 
V 80 1.63 6.79 136 114 
Me 80 1.18 4.92 63 70 
40 1.78 7.42 25 61 
40 0.815 3.40 66 
Mean for 80 mg = 131 








Ma 16.86 0.0579 12.0 
Bu 108.2 0.165 4.2 
V 21.65 0.0651 10.6 
Me 45.33 0.164 4.2 
T 6.082 0.153 4.5 
H 43.91 0.105 6.6 
Bo 33.57 0.257 2.7 
Mean 39.4 0.138 6.4 
CV (%)85.2 50.0 
*The 130 used is the mg/kg oral dose shown in column 3. The D. used was 0.24 mg/kg (0.1 bolus and 0.14 infusion). These dose ratios 
were used when Z was involved, but ratios 2.4 times larger were used with C; values since they corresponded to Di, values of 0.1 mg/kg. 
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Table VI. Prediction of plasma verapamil Cs for oral therapy from verapamil plasma 
concentrations measured after single intravenous doses 
*The predicted verapamil concentrations for intravenous therapy correspond to those expected for doses equivalent to the oral doses (Table 
IV). 'C(B) refers to predicted steady-state concentration for bolus doses of 0.1 mg/kg given every T hr where t is the time after dosing at 
steady state. ts(B + I) refers to the predicted concentration for a bolus + infusion regimen as used in this study but repeated every 7 hr to 
steady state. t(B) and t(B + I) refer to predicted concentrations after single bolus doses and bolus + infusion doses. 
*r is the correlation coefficient for the linear regression of Y (the observed verapamil CiVn shown in Table IV) and the X shown in columns 2 
and 3 above. 
*The mean absolute (sign ignored) deviation of the predicted from the observed verapamil plasma concentration. 
§P < 0.001. 
lip < 0.01. 
11In these correlations only terminal postinfusion data were used (see Tables I and V). 
Table VII. Plasma concentrations of 
verapamil and norverapamil in subject Bo 
after 40 mg of oral verapamil 24 hr 
after a bolus dose of 0.1 mg /kg and 
an infusion of 0.14 mg /kg over 
20 min 
*Data from 0.25 to 4 hr were fitted by the equation: C = 
70.36e-°.3371 + 15.62e-283t where t = time of oral dosing. The 
higher value of 0.337 than those shown for X, in Table II suggests 
that blood was not sampled long enough to observe the terminal log- 
linear phase. 
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them. This accounts for the unit of measure in 
Table III being liters per minute or liters rather 
than liters per minute per kilogram or liters per 
kilogram. We also found no significant correla- 
tions of in Y with in X where Y = clearance, 
volume of distribution at steady state, volume 
of distribution area, volume of distribution ex- 
trapolated, t1/2, or mean residence time and X = 
body weight. 
The last rows of Tables II and III indicate that 
verapamil should not be treated as a single ex- 
ponential or one-compartment open model drug 
in therapeutic drug monitoring. At least in the 
seven children we studied, the error in such an 
approximation varies greatly from patient to 
patient. 
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